At the heart of the controversy is Regeneron's alleged practice of paying credit card fees to distributors, on the condition that these fees were not passed on to Eylea customers. This arrangement, ...
Zacks.com on MSN1h
Regeneron Gets Positive CHMP Opinion for Multiple Myeloma DrugRegeneron Pharmaceuticals, Inc. REGN obtained positive opinion for its pipeline candidate linvoseltamab from the European ...
A lawsuit was filed for certain investors in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shares. Investors who purchased shares of Regeneron ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback